RxDoctor Payments Data

F Omar Tordilla, MD

Family Medicine · Escondido, CANPI 1225063795

Payments from drug & device makers

$1,631in general payments, 2019–2025

Across 129 payments — averaging $12.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$758
  • AstraZeneca$191
  • Biotronik Inc.$124
  • Lilly USA, LLC$106
  • GSK$94
  • Otsuka America Pharmaceutical, Inc.$70
  • plus $287 from 10 others

What the payments were for

  • Food & beverage$1,631100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,631 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$359,592
Medicare patients
309
Services billed
2,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$158,564
OzempicSemaglutide37$44,858
JardianceEmpagliflozin49$35,598
XareltoRivaroxaban69$35,584
CreonLipase/Protease/Amylase20$31,522
JanuviaSitagliptin Phosphate68$29,857
RybelsusSemaglutide12$17,043
EntrestoSacubitril/Valsartan32$15,650
TradjentaLinagliptin30$13,255
Lansoprazole19$8,661
AranespDarbepoetin Alfa In Polysorbat26$8,585
Emgality PenGalcanezumab-Gnlm12$8,417
Spiriva RespimatTiotropium Bromide16$8,242
MyrbetriqMirabegron12$6,057
Levothyroxine Sodium569$5,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$158,564227 claims
Novo NordiskOzempic, Rybelsus$758$61,90149 claims
Johnson & JohnsonXarelto$11$35,58469 claims
NovartisEntresto$70$15,65032 claims
AmgenAranesp$30$8,58526 claims
Astellas Pharma US IncMyrbetriq$27$6,05712 claims
AstraZenecaSymbicort$191$3,54116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Escondido

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →